Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gastrointestinal 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 17Breast Neoplasms 15Leukemia 14Precursor Cell Lymphoblastic Leukemia-Lymphoma 13Leukemia, Myeloid, Chronic-Phase 10Recurrence 8Prostatic Neoplasms 8Carcinoma, Non-Small-Cell Lung 8Lung Neoplasms 7Neoplasm Metastasis 6Leukemia, Lymphocytic, Chronic, B-Cell 6Melanoma 5Burkitt Lymphoma 5Pancreatic Neoplasms 4Leukemia, Myeloid, Acute 4Glioblastoma 4Blast Crisis 4Squamous Cell Carcinoma of Head and Neck 3Ovarian Neoplasms 3Neoplasms 3Lymphoma 3Gliosarcoma 3Sarcoma 2Salivary Gland Neoplasms 2Rhabdomyosarcoma 2Rectal Neoplasms 2Polycythemia Vera 2Oligodendroglioma 2Multiple Myeloma 2Lymphoma, Large B-Cell, Diffuse 2

Interventions

Sunitinib 16Imatinib Mesylate 13nilotinib 8ripretinib 4regorafenib 4avapritinib 34-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 3pexidartinib 2pembrolizumab 2Bevacizumab 2trametinib 1tinostamustine 1spartalizumab 1romidepsin 1ponatinib 1pazopanib 1palbociclib 1olaratumab 1guadecitabine 1ferric carboxymaltose 1epacadostat 1dabrafenib 1cediranib 1Surveys and Questionnaires 1Surgical Procedures, Operative 1Sorafenib 1STA 9090 1Observation 1Iron-Dextran Complex 1Indocyanine Green 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Gastrointestinal Stromal Tumors × Dasatinib × Clear all
NCT00464620 2018-11-23

Trial of Dasatinib in Advanced Sarcomas

Sarcoma Alliance for Research through Collaboration

Phase 2 Completed
366 enrolled 16 charts
GastrointestinalSarcoma

Chondrosarcoma, Chordoma, Hemangiopericytoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Giant Cell Tumor of Bone, Sarcoma, Alveolar Soft Part, Neurofibrosarcoma, Gastrointestinal Stromal Tumors, Solitary Fibrous Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡